Chemotherapy for Relapsed Hodgkin's Disease
Author Information
Author(s): T.J. Perren, P.J. Selby, S. Milan, M. Meldrum, T.J. McElwain
Primary Institution: Institute of Cancer Research, Royal Marsden Hospital
Hypothesis
The HOPE-Bleo regimen is an effective treatment for relapsed or resistant Hodgkin's disease.
Conclusion
The HOPE-Bleo regimen is an effective treatment for relapsed or resistant Hodgkin's disease, with a low probability of carcinogenesis and infertility.
Supporting Evidence
- 26 patients achieved complete remission (CR) and 10 achieved partial remission (PR).
- The median duration of CR was 22 months.
- Median survival for all patients was 48 months.
- Two patients died due to treatment-related complications.
Takeaway
Doctors used a special mix of medicines to help people with a type of cancer called Hodgkin's disease, and many of them got better.
Methodology
Patients received a combination of adriamycin, vincristine, prednisolone, etoposide, and bleomycin, with treatment cycles based on blood counts.
Limitations
The study had a small sample size and was limited to patients who had previously received chemotherapy.
Participant Demographics
Median age was 27 years, with a range from 12 to 71 years; 30 were male and 14 female.
Statistical Information
P-Value
0.003
Confidence Interval
45-74%
Statistical Significance
p=0.003
Want to read the original?
Access the complete publication on the publisher's website